Brocard J, Feil R, Chambon P, Metzger D
Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP, Collège de France, BP 163,67404 Illkirch Cedex, C. U. de Strasbourg, France.
Nucleic Acids Res. 1998 Sep 1;26(17):4086-90. doi: 10.1093/nar/26.17.4086.
We have developed a new ligand-dependent chimeric recombinase (Cre-GRdex) by fusing the site-specific Cre recombinase to the ligand binding domain (LBD) of a mutant human glucocorticoid receptor (GRdex). The synthetic glucocorticoid receptor (GR) ligands dexamethasone, triamcinolone acetonide and RU38486efficiently induce recombinase activity in F9 murine embryonal carcinoma cells expressing constitutively Cre-GRdex. In contrast, no recombinase activity was detected in the absence of ligand or in the presence of the natural GR ligands corticosterone, cortisol or aldosterone. Moreover, physiological concentrations of these natural GR ligands do not affect Cre-GRdexrecombinase activity induced by dexamethasone. Thus, as previously shown using Cre-oestrogen receptor (ER) fusion proteins, Cre-GRdexmight be useful for achieving loxP site-directed mutagenesis in cultured cells and spatio-temporally controlled somatic cell mutagenesis in transgenic mice.
我们通过将位点特异性Cre重组酶与突变型人糖皮质激素受体(GRdex)的配体结合域(LBD)融合,开发了一种新的配体依赖性嵌合重组酶(Cre-GRdex)。合成糖皮质激素受体(GR)配体地塞米松、曲安奈德和RU38486可在组成型表达Cre-GRdex的F9小鼠胚胎癌细胞中有效诱导重组酶活性。相比之下,在无配体存在或存在天然GR配体皮质酮、皮质醇或醛固酮的情况下未检测到重组酶活性。此外,这些天然GR配体的生理浓度不影响地塞米松诱导的Cre-GRdex重组酶活性。因此,如先前使用Cre-雌激素受体(ER)融合蛋白所表明的那样,Cre-GRdex可能有助于在培养细胞中实现loxP位点定向诱变以及在转基因小鼠中进行时空控制的体细胞诱变。